Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...
The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback